What they were paid
Sarepta Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $80,000 | $237,561 | $236,905 | $0 | $554,466 |
| FY2024 | $78,331 | $237,525 | $248,782 | $0 | $564,638 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sarepta Therapeutics, Inc. DEF 14A filed April 24, 2026, accession 0001193125-26-177247, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Sarepta Therapeutics pays directors a $60,000 cash retainer and $475,000 in equity.
Committees
FY2025 · as the proxy prints themCompensation · Research and Development
The rest of the Sarepta Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Deirdre Connelly | Independent Director | $558,153 |
| Douglas S. Ingram | Director | $0 |
| Hans Wigzell | Independent Director | $562,466 |
| Kathryn J. Boor | Independent Director | $552,466 |
| M. Kathleen Behrens | Chair of the Board | $603,923 |
| Michael Chambers | Independent Director | $544,466 |
| Richard J. Barry | Independent Director | $577,279 |
| Stephen L. Mayo | Independent Director | $556,966 |
The full Sarepta Therapeutics compensation record
free company briefThis page is one director within Sarepta Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat